Lichen China Limited (NASDAQ:LICN – Get Free Report) saw a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 91,000 shares, a drop of 16.9% from the October 15th total of 109,500 shares. Based on an average trading volume of 352,300 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.4% of the shares of the company are short sold.
Lichen China Stock Performance
Shares of Lichen China stock opened at $1.88 on Friday. Lichen China has a 52-week low of $0.50 and a 52-week high of $2.44. The stock’s 50-day simple moving average is $1.89 and its 200 day simple moving average is $1.76.
Institutional Trading of Lichen China
A hedge fund recently bought a new stake in Lichen China stock. XTX Topco Ltd acquired a new stake in Lichen China Limited (NASDAQ:LICN – Free Report) in the second quarter, according to its most recent filing with the SEC. The fund acquired 37,315 shares of the company’s stock, valued at approximately $54,000. XTX Topco Ltd owned approximately 0.14% of Lichen China at the end of the most recent quarter.
Lichen China Company Profile
Lichen China Limited, together with its subsidiaries, operates as an investment holding company, provides financial and taxation, education support, and software and maintenance services in the People's Republic of China and internationally. The company offers financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation services; and education support services, including marketing, operational, and technical support, as well as sells teaching and learning materials.
Featured Articles
- Five stocks we like better than Lichen China
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- What is the FTSE 100 index?
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- Financial Services Stocks Investing
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Lichen China Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lichen China and related companies with MarketBeat.com's FREE daily email newsletter.